RESULTS: Thirty-eight patients were prospectively enrolled in our study with a median age of 12.5 months (IQR 4-39), median body mass index (BMI) of 17 , and predominantly female (68%). Median fluoroscopic time was 54 seconds (IQR 36-72). The median dose area product (mGy*m2) was 4.4 (IQR 2.6-7.5) and median radiation dose absorbed at the skin entrance per dosimeter (mGy) was 0.33 (IQR 0.13-0.5, range .01-2.9) (p¼0.01). There was a positive correlation between the air kerma, 0.2 mGy (IQR 0.17-0.39) and absorbed dose measured by dosimeter, 0.33 mGy (IQR 0.13-0.5) (r ¼ 0.67, p < 0.001). There was no correlation between absorbed dose and BMI (r ¼ 0.14, p ¼ 0.4), and fluoroscopy time and BMI (r ¼ 0.24, p ¼ 0.15). There was a positive correlation between fluoroscopy time and absorbed dose (r ¼ 0.64, p < 0.001).
INTRODUCTION AND OBJECTIVES: The Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial showed a 50% reduction in the risk for recurrent urinary tract infection (UTI) in children who received prophylaxis compared to placebo. This conclusion is heavily debated. We reevaluated the RIVUR data using a validated risk stratification model. METHODS: Data from all 607 children were used. We stratified the children into low, intermediate and high risk categories based on gender, circumcision status, VUR grade and bladder bowel dysfunction. Febrile or symptomatic UTI recurrence in our stratified placebo and prophylaxis groups were compared using Fisher's exact test. Kaplan-Meier curves and a log-rank test was used for time-toevent analysis.
RESULTS: There were 389 (65%), 132 (22%) and 50 (8%) children stratified into low, intermediate and high risk categories. The rate of recurrent UTI was not significantly different in low risk children receiving either placebo or prophylaxis (Table 1) . Whereas intermediate risk children receiving prophylaxis had a 20% absolute reduction in recurrence compared to placebo. Similarly, there were half as many recurrent UTIs in high risk children on prophylaxis; however this was not significant due to the small sample size. Time-to-event analysis showed no difference in recurrence between the stratified categories with placebo or prophylaxis (p¼0.045).
CONCLUSIONS: The majority (65%) of the children in the RIVUR trial fell into the low risk category and do not benefit from prophylaxis, while intermediate risk children receiving prophylaxis showed a 20% absolute reduction in recurrence. These results favor an individualized approach for the optimal management of children with vesicoureteral reflux. A CRITICAL REVIEW OF RECENT CLINICAL PRACTICE  GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF  PAEDIATRIC URINARY TRACT INFECTION USING THE  AGREE LI TOOL Michael Chua*, Jessica Ming, Joana Dos Santos, Toronto, Canada; Shang-Jen Chang, Taipei, Taiwan; Jan Michael Silangcruz, Quezon City, Philippines; Mark Bayley, Martin Koyle, Toronto, Canada INTRODUCTION AND OBJECTIVES: There are many clinical practice guidelines (CPGs) published recently pertaining to the management of pediatric urinary tract infection (pUTI). Concerns regarding the quality, credibility and applicability of these CPGs have been raised due to the inconsistencies of recommendations between them. We hypothesized that these differences may be due to variation in the quality of the guideline development process therefore the aim of this project was to determine the quality of the CPGs on pUTI using AGREE II (Appraisal of Guidelines Research and Evaluation) instrument.
Source of Funding: None
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METHODS: A systematic literature search was performed to identify CPGs for pUTI published from 2007-2016. Eligible CPGs were independently assessed and appraised by 5 physician reviewers using AGREE II tool. The CPGs were assessed for domains and summarized for overall quality by each reviewer. The appraisal score for each guideline was extrapolated for each AGREE domain and in overall total. CPGs were then ranked accordingly and domains were assessed for quality. Domain score less than 70 is considered low. Inter-rater reliability was assessed using Inter-class coefficient (ICC) and statistical significance was set at 0.5.
RESULTS: A total of 13 CPGs were critically reviewed. Amongst the 5 reviewers, there was a high degree of inter-rater reliability. The average measure ICC was 0.922 with a 95% confidence interval from 0.826 to .0.973 (F(12,48)¼ 12.806, p<.0001). The Spanish guideline for pediatric UTI, American Association of Pediatrics (AAP) and National Institute for Health and Clinical Excellence (NICE) guidelines consistently scored high on all AGREE domains. 10/13 CPGs had scores <70 for the domains of applicability, while the domains of stakeholder involvement and rigor of development were low in 9 CPGs.
CONCLUSIONS: The CPGs from Spain, AAP and NICE scored highly on the AGREE II indicators of quality of the CPG development process. Domains of applicability, stakeholder involvement and rigor of development were suboptimal quality wise in the majority of the most recently available CPGs for pUTI. This leads to potential confusion for the intended audience for whom these guidelines have been developed. Clinicians are recommended to consider these findings when selecting pUTI guidelines for use in practice.
Source of Funding: none
MP61-13 COMPLIANCE WITH THE 2011 AAP UTI GUIDELINES FOR VCUG ORDERING BY PROVIDER SPECIALTY
Deborah L Jacobson*, Rachel Shannon, Jared R Green, Cynthia L Rigsby, Sangeeta K Schroeder, Neha R Malhotra, Ilina Rosoklija, Jane L Holl, Earl Y Cheng, Emilie K Johnson, Chicago, IL INTRODUCTION AND OBJECTIVES: Controversy exists regarding the 2011 AAP guidelines for voiding cystourethrogram (VCUG) ordering in the setting of febrile urinary tract infection (UTI) in children aged 2-24 months. We aimed to (1) determine rates of provider compliance by specialty and (2) evaluate the association between guideline adherence and VCUG result.
METHODS: We completed a retrospective review of all patients undergoing VCUG at our institution from 1/12-12/13. Patients with neurogenic bladder, known genitourinary abnormality, known vesicoureteral reflux, or those >18 years of age were excluded. The primary outcome was adherence to the 2011 guidelines for VCUG acquisition. Relationships between provider specialty (urology vs Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e803 pediatrics), patient demographics, VCUG outcome, and guideline adherence were evaluated with bivariate statistics and logistic regression. Subgroup analysis of patients 2-24 months was completed. RESULTS: VCUGs from 1,115 consecutive patients were reviewed. 747 patients were excluded (243 for known genitourinary anomalies, 262 for known VUR, 171 for antenatal hydronephrosis without UTI, and 71 for incomplete records). 368 patients (67% female, median age 12.5 months [range 4.6-49]) were included in the primary analysis. 188 patients (51%) were aged 2-24 months. VCUG ordering patterns were similar among urologists and nephrologists (35% of VCUGs) and among pediatricians and other specialists (65% of VCUGs). Thus, these specialties were grouped for analysis. 61% of VCUGs were ordered in accordance with the 2011 AAP guidelines; urologists/nephrologists were more likely to adhere to ordering guidelines than pediatricians/other specialists (76% vs 52%, OR 2.93 [1.8-4.7], p<0.0001). Subgroup analysis in patients 2-24 months revealed similar findings (76% vs 52%, OR 3.0 [1.5-6.1], p¼0.002). VCUGs were abnormal in 117/368 patients (32%) overall and 49/188 (26%) patients 2-24 months. Guideline adherence was associated with increased likelihood of abnormal VCUG among all patients (36% of appropriately ordered vs. 25% of inappropriately ordered studies were abnormal, p¼0.03), but there was no association in patients 2-24 months (26% of studies were abnormal in each group, p¼0.98).
CONCLUSIONS: At our institution, 2011 AAP UTI guideline adherence for VCUG ordering was more likely among urologists/nephrologists than pediatricians. While adherence increased the diagnostic yield of VCUG studies in the full cohort, there was no association in children 2-24 months. Further multi-center evaluation is necessary to determine whether ordering recommendations should be revised.
Source of Funding: None
MP61-14 EFFECT OF NEWBORN CIRCUMCISION ON URINARY TRACT INFECTIONS IN PATIENTS WITH AN EARLY DIAGNOSIS OF HYDRONEPHROSIS.
Jonathan Ellison*, Geolani Dy, Ben Fu, Sarah Holt, John Gore, Paul Merguerian, Seattle, WA INTRODUCTION AND OBJECTIVES: Boys with known urinary tract abnormalities may derive a greater benefit of newborn circumcision for prevention of urinary tract infection (UTI) than the general population. However, the effect of newborn circumcision on UTI in this population is not well characterized across the spectrum of etiologies for hydronephrosis (HN). We hypothesized that in boys with an early diagnosis of HN rates of UTI will be reduced by newborn circumcision while patients with vesicoureteral reflux (VUR) and posterior urethral valves (PUV) will realize the greatest benefit of the intervention.
METHODS: Claims from MarketScanâ, an employer-based dataset of privately insured patients, were used to identify boys with HN or HN-related diagnoses (PUV, VUR, ureteropelvic junction obstruction [UPJO], ureterocele) within the first 30 days of life. Patients with severe urologic comorbidities were excluded as were children with inadequate longitudinal enrollment for follow-up and/or UTI within the first 30 days of life. The primary outcome was the rate of UTIs within the first year of life, comparing circumcised to uncircumcised boys as an entire group and across diagnostic sub-groups, adjusting for region, insurance type, year of birth, and infant comorbidity.
RESULTS: A total of 5561 boys met inclusion criteria, including 2386 (42.9%) undergoing newborn circumcision and 3175 (57.1%) uncircumcised boys. Boys with > 2 comorbidities were more frequently uncircumcised (6.1% vs 2.5%, p < 0.001). Overall rates of UTI were lower in circumcised boys as compared to uncircumcised boys (5.9% vs 16.1%, p < 0.001) with an adjusted odds ratio for a UTI of 0.35 (0.29-0.43) in the circumcised population. Circumcision was associated with a decreased odds of UTI across several diagnostic subgroups including general HN, VUR, and UPJO, as seen in the Table. CONCLUSIONS: Newborn circumcision is associated with a 35% lower rate of UTI in boys with an early diagnosis of HN. This association is seen for across all most diagnostic sub-groups for HN, adjusting for measurable confounding variables. Lack of significant association in boys with PUV and ureterocele may be due to low rates of these diagnosis in this cohort. Future work to prospectively evaluate the benefit of circumcision in this population at a granular level is needed. RESULTS: 98 patients (143 ureters, 85% single system, 79% female, median age 5 years) underwent RALUR by 9 surgeons. Indications included VUR non-resolution (43%), renal scarring (37%), and breakthrough UTI (27%). Highest VUR grade was I/II in 15%, III in 45%, IV/V in 38%, and ungraded in 2%. Bowel/bladder dysfunction was noted in 45%. Variability in multiple technical details was identified (Table 1) . 17 patients (17%) had clinical failure: 9 (9%) VUR Grade II, 9 (9%) fUTI, 2 (2%) fUTI + persistent VUR, and 2 (2%) required reoperation. None of the technical factors in Table 1 were associated with clinical failure (e.g., Table 2 ).
Source of
CONCLUSIONS: Patients undergoing RALUR at 4 RRC sites had an 83% clinical success rate, comparable to historical open surgery rates. It was feasible to collect some technical details retrospectively; technique variability was documented. This initial series found no association between technical factors and clinical outcomes. Future plans include prospectively evaluating associations between technical factors and RALUR outcomes, and developing standardized technique recommendations.
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